P-014 - RATIONALE FOR DOSAGE ADJUSTMENT OF LEFAMULIN IN PATIENTS WITH HEPATIC IMPAIRMENT: INCREASE IN FREE DRUG EXPOSURE.

T. Bensman, S. Jang; US Food and Drug Administration, Silver Spring, MD, USA.

Presenting Author(s)

Timothy Bensman, PharmD, PhD

Clinical Pharmacologist
US Food and Drug Administration
Bethesda, Maryland, United States